Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial.
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M Dr, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano de Colella JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hébraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Bruiec C, Frenzel L, Vekemans MM, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Perrot A, et al. Blood. 2025 Jan 22:blood.2024026230. doi: 10.1182/blood.2024026230. Online ahead of print. Blood. 2025. PMID: 39841461
Daratumumab for maintenance in myeloma.
Touzeau C, Perrot A. Touzeau C, et al. Among authors: perrot a. Blood. 2025 Jan 16;145(3):251-252. doi: 10.1182/blood.2024026888. Blood. 2025. PMID: 39820980 No abstract available.
Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage.
Dupont S, Lebas H, Mavouna S, Pascal E, Perrot A, Cogo A, Bourrienne MC, Farkh C, Solo Nomenjanahary M, Ollivier V, Zemali F, Nieswandt B, Loyau S, Jandrot-Perrus M, Camerer E, Desilles JP, Mazighi M, Boulaftali Y, Ho-Tin-Noé B. Dupont S, et al. Among authors: perrot a. J Am Heart Assoc. 2025 Jan 17:e034207. doi: 10.1161/JAHA.123.034207. Online ahead of print. J Am Heart Assoc. 2025. PMID: 39818980 Free article.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Moreau P, et al. Among authors: perrot a. Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02506-1. Online ahead of print. Leukemia. 2025. PMID: 39815052
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, Chateleix C, Moreau S, Karlin L, Jacquet C, Manier S, Hulin C, Decaux O, Richez V, Chalopin T, Mohty M, Orsini-Piocelle F, Caillot D, Sonntag C, Vignon M, Bobin A, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Touzeau C, et al. Among authors: perrot a. Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19978. Online ahead of print. Br J Haematol. 2025. PMID: 39757748
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, Vignon M, Godet S, Chalopin T, Moyer P, Chalayer E, Orsini Piocelle F, Mariette C, Croizier C, Sohn C, Dib M, Le Calloch R, Ali-Ammar N, Loirat M, Benbrahim O, Payssot A, Trebouet A, Perrot A, Leleu X, Mohty M. Malard F, et al. Among authors: perrot a. Blood Cancer J. 2024 Dec 18;14(1):219. doi: 10.1038/s41408-024-01200-w. Blood Cancer J. 2024. PMID: 39695076 Free PMC article. No abstract available.
Transplant in myeloma: who, when, and why?
Perrot A. Perrot A. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):561-568. doi: 10.1182/hematology.2024000580. Hematology Am Soc Hematol Educ Program. 2024. PMID: 39643987 Free PMC article. Review.
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Richardson PG, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, Capra M, D'Agostino M, Sonneveld P, Bisht K, Fukao T, Zhang R, Tada K, Tekle C, Macé S, Klippel Z, van de Velde H, Moreau P. Richardson PG, et al. Among authors: perrot a. Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w. Blood Cancer J. 2024. PMID: 39609425 Free PMC article. Clinical Trial.
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, Dony A, Mohty M, Roussel M, Manier S, Orsini-Piocelle F, Bauschert L, Bobin A, Frenzel L, Vincent L, Breal C, Eveillard JR, Gerome T, Tiab M, Chalayer E, Belkhir R, Mariette C, Moyer P, Chalopin T, Cherel B, Montes L, Coste A, Tabrizi R, Karlin L, Robu D, Huguet A, Harel S, Moreau P. Perrot A, et al. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286118. Online ahead of print. Haematologica. 2024. PMID: 39568438 Free article.
348 results